Skip to content

Psilocybin: all studies

Page 159 of 439: studies 1,581 to 1,590 of 4,389, newest first. Back to the psilocybin overview

Research

The emerging role of psilocybin and MDMA in the treatment of mental illness

Expert Review of Neurotherapeutics September 21, 2020 Hartej Gill, Barjot Gill, David C J Chen-Li et al. 62 citations

Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety,...

Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin

Journal of Psychoactive Drugs September 15, 2020 Tracey Varker, Loretta Watson, Kari Gibson et al. 57 citations

The aim of this systematic review was to examine the efficacy of MDMA, ketamine, LSD, and psilocybin for the treatment of posttraumatic stress disorder (PTSD). A search of four databases for English language, peer-reviewed literature published from inception to 18th October 2019 yielded 2,959 records, 34 of which were screened on full-text. Observational studies and RCTs which tested the...

Psilocybin rescues sociability deficits in an animal model of autism

bioRxiv (Cold Spring Harbor Laboratory) September 10, 2020 Irene Mollinedo-Gajate, Chenchen Song, Marcos Sintes-Rodriguez et al. 6 citations preprint

Abstract Autism spectrum disorder (ASD) is characterized by core deficits in social interaction. The classic serotonergic psychedelic psilocybin has been suggested as a therapeutic agent that may ameliorate in the core symptomology of ASD. We found that the acute response to psilocybin was attenuated in the prenatal valproic acid exposure mouse model of ASD, and importantly, psilocybin rescued...

Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases—A Systematic Review and Meta-Analysis of Clinical Trials

Biomedicines September 5, 2020 Ana Sofia Vargas, Ângelo Luís, Mário Barroso et al. 121 citations

Psilocybin is a naturally occurring tryptamine known for its psychedelic properties. Recent research indicates that psilocybin may constitute a valid approach to treat depression and anxiety associated to life-threatening diseases. The aim of this work was to perform a systematic review with meta-analysis of clinical trials to assess the therapeutic effects and safety of psilocybin on those...

DOI: 10.3390/biomedicines8090331 (opens in new tab) Psilocybin Anxiety Context archaeology Beck depression inventory +6

Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention.

Neuroimage September 1, 2020 Frederick S. Barrett, Samuel R Krimmel, Roland R. Griffiths et al. 191 citations

Psychedelic drugs, including the serotonin 2a (5-HT2A) receptor partial agonist psilocybin, are receiving renewed attention for their possible efficacy in treating a variety of neuropsychiatric disorders. Psilocybin induces widespread dysregulation of cortical activity, but circuit-level mechanisms underlying this effect are unclear. The claustrum is a subcortical nucleus that highly expresses...

DOI: 10.1016/j.neuroimage.2020.116980 (opens in new tab) Full text (opens in new tab) Psychedelics Serotonin 2a receptor Claustrum connectivity Psychedelic effects +1

The Psilocin (4-hydroxy-N,N-dimethyltryptamine) and Bufotenine (5-hydroxy-N,N-dimethyltryptamine) Case: Ensuring the Correct Isomer has Been Identified.

Journal of Forensic Sciences September 1, 2020 Tehila Mishraki-Berkowitz, Esti Kochelski, Pierce V. Kavanagh et al. 12 citations

Psilocin (4-hydroxy-N,N-dimethyltryptamine, 4-HO-DMT) and bufotenine (5-hydroxy-N,N-dimethyltryptamine, 5-HO-DMT), which are both naturally occurring compounds, are classified as controlled substances in numerous countries due to their pharmacological activities and recreational usage. There are two other benzene ring regioisomers, 6-hydroxy-N,N-dimethyltryptamine (6-HO-DMT) and...

DOI: 10.1111/1556-4029.14368 (opens in new tab) Full text (opens in new tab) Psilocin Bufotenine Controlled substances Hydroxy-N,N-Dimethyltryptamine Ho-DMT +9

P300‐mediated modulations in self–other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self–other overlap

Human Brain Mapping August 21, 2020 Lukasz Smigielski, Michael Kometer, Milan Scheidegger et al. 42 citations

Abstract The concept of self and self‐referential processing has a growing explanatory value in psychiatry and neuroscience, referring to the cognitive organization and perceptual differentiation of self‐stimuli in health and disease. Conditions in which selfhood loses its natural coherence offer a unique opportunity for elucidating the mechanisms underlying self‐disturbances. We assessed the...

DOI: 10.1002/hbm.25174 (opens in new tab) Psilocybin Anterior cingulate cortex Cognition Cognitive psychology +6

Case Report: Resolution of Rheumatoid Arthritis in a Patient Consuming Psilocybin Mushrooms

Journal of Healthcare August 19, 2020 S Lin Denise 2 citations

This was a retrospective database analysis of all paediatric (< 18-years) intubations performed by HEMS physicians during a six-year period (2012-2017). The recorded findings included patient demographics, operator background, airway interventions (including intubation attempts), video-assisted intubation, and complications.

DOI: 10.36959/569/456 (opens in new tab) Full text (opens in new tab) Psilocybin Demographics Rheumatoid arthritis Psychological intervention +3

Delayed Anxiolytic-Like Effects of Psilocybin in Male Mice Are Supported by Acute Glucocorticoid Release

bioRxiv (Cold Spring Harbor Laboratory) August 14, 2020 N. Jones, Zarmeen Zahid, Sean M. Grady et al. 9 citations preprint

Abstract Despite observed correlations between acute glucocorticoid release, self-reported anxiety, and long-term treatment outcomes for human studies using psilocybin-assisted psychotherapy approaches, the mechanistic relationship between psychedelic-dependent stress and subsequent behavioral responses remains unclear. Using rodents, direct manipulation of stress-associated hormone responses...

The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)

August 13, 2020 Jeffrey Guss, Robert Krause, Jordan Sloshower 86 citations preprint

The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider regarding the use of psychedelic- assisted therapy in the treatment of Major Depressive Disorder (MDD). In particular, this manual illustrates a mode of utilizing Acceptance and Commitment Therapy (ACT) as a therapeutic framework for...